Discovery and Optimization of a Novel Series of Pyrazolyltetrahydropyran N-type Calcium Channel (Ca 2.2) Blockers for the Treatment of Pain
Overview
Authors
Affiliations
A novel series of pyrazolyltetrahydropyran N-type calcium channel blockers are described. Structural modifications of the series led to potent compounds in both a cell-based fluorescent calcium influx assay and a patch clamp electrophysiology assay. Representative compounds from the series were bioavailable and showed efficacy in the rat CFA and CCI models of inflammatory and neuropathic pain.
Garza-Carbajal A, Bavencoffe A, Herrera J, Johnson K, Walters E, Dessauer C Proc Natl Acad Sci U S A. 2024; 121(34):e2405465121.
PMID: 39145932 PMC: 11348325. DOI: 10.1073/pnas.2405465121.
The mechanism of USP43 in the development of tumor: a literature review.
Zhao Z, Liu M, Lin Z, Zhu M, Lv L, Zhu X Aging (Albany NY). 2024; 16(7):6613-6626.
PMID: 38613804 PMC: 11042928. DOI: 10.18632/aging.205731.
Xu Y, Wijeratne E, Calderon-Rivera A, Loya-Lopez S, Perez-Miller S, Khanna R ACS Omega. 2023; 8(22):20085-20095.
PMID: 37305315 PMC: 10249386. DOI: 10.1021/acsomega.3c02302.
Xue Y, Li M, Hu J, Song Y, Guo W, Miao C Cell Death Dis. 2022; 13(9):812.
PMID: 36137995 PMC: 9500045. DOI: 10.1038/s41419-022-05174-0.